Clinician-in-the-loop
PROBRAIN prepares the assessment; the physician retains final judgment.
00
EARLIER SIGNAL SYNTHESIS
Built to catch Alzheimer's years earlier.
PROBRAIN fuses blood biomarkers, cognition, imaging, comorbidities, and caregiver signals into one explainable clinical assessment, prepared for a clinician to review and sign off.
Research preview. Clinical decision support, not autonomous diagnosis. No regulatory or accuracy claims.
01 / WHY NOW
The disease does not arrive as one clean signal.
Alzheimer's and related dementias create clinical, family, and economic pressure at global scale. Yet the data required to reason about one patient often arrives separately: one lab result, one cognitive score, one imaging summary, one history.
- 57M
- people were living with dementia worldwide in 2021.
- ≈10M
- new cases occur globally each year.
- $1.3T
- estimated global economic cost in 2019.
THE OPERATING GAP
FDA reference, May 2025
Blood-based biomarkers are entering clinical practice, but even cleared tests are intended to be interpreted with other patient information—not as stand-alone diagnosis.
02 / THE SYSTEM
One intelligence layer.
All signals in view.
PROBRAIN is being built to standardize a patient state, route it through specialist reasoning, surface uncertainty, and prepare one clinician-ready assessment with source traceability.
CLINICAL INPUTS
- 01Labs & biomarkerspTau, amyloid ratios, genetics, metabolic context
- 02Brain imagingMRI and PET summaries, volumetry, clinician findings
- 03CognitionMMSE, MoCA, assessments, longitudinal change
- 04Clinical contextComorbidities, medications, notes, history
- 05Caregiver / PROFunctional decline, behaviour, observed change
PROBRAIN CORE
01Input & integrationIngest files, forms, summaries, and structured feeds.
02Workflow orchestrationCreate the patient state and route specialist review.
03Truth & referenceRetain evidence, ranges, provenance, and staging logic.
04Multi-agent reasoningSynthesize biomarkers, cognition, imaging, context, and change.
05Fusion, safety & auditScore confidence, flag conflict, and preserve traceability.
MISSING DATA / SURFACED
CONFLICT / FLAGGED
PROVENANCE / RETAINED
CLINICIAN REVIEW
- AEvidence summaryOne patient view across every connected signal.
- BRisk interpretationEvidence-linked reasoning with uncertainty markers.
- CTrajectory estimateProgression signal prepared for clinical review.
- DCare considerationsQuestions, follow-up paths, and care context.
- ETrial pre-screeningSuitability cues before costly confirmatory work.
03 / WORKFLOW
From fragmented data to clinical action.
A compact workflow designed for the places data already moves: diagnostic labs, hospitals, memory clinics, specialist practices, and research programs.
-
01
Connect the sources
Bring in lab reports, imaging summaries, cognitive scores, notes, comorbidities, and caregiver observations—without forcing every partner into the same starting system.
INPUT / PDF · FORM · FEED · SUMMARY -
02
Standardize the patient state
Normalize the case into one canonical snapshot. Identify what is present, what conflicts, and what remains missing before reasoning begins.
STATE / COMPLETE · CONFLICT · MISSING -
03
Reason across specialist agents
Biomarker, cognition, imaging, comorbidity, and longitudinal-change agents contribute to a shared fusion layer instead of producing isolated scores.
FUSION / 5 SPECIALIST AGENTS -
04
Prepare the clinical review
Deliver an explainable assessment with confidence markers, supporting evidence, open questions, and a source trace. Final judgment and sign-off remain with the clinician.
OUTPUT / REVIEW · SIGN-OFF · AUDIT
04 / TRUST BY DESIGN
Clinical judgment stays with the clinician.
The product is in development as decision support. Any clinical deployment would require validation, governance, privacy review, and relevant regulatory pathways.
Confidence-scored
Outputs carry uncertainty markers instead of presenting false certainty.
Explainable & auditable
Every conclusion is designed to retain evidence links, source provenance, and review history.
Safe with incomplete data
Missing and conflicting inputs are surfaced as part of the assessment.
India-first deployment
Workflow planning accounts for document-heavy, bilingual, and distributed clinical environments.
Pilot-led validation
Product claims are intended to advance only through lab co-builds and clinical studies.
05 / ENTRY POINTS
Built for the first places the data already flows.
A lab-first wedge creates the route into hospitals, specialist practices, and trial workflows—one core intelligence layer, adapted to each partner's operating model.
Partner
What PROBRAIN adds
Commercial path
Diagnostic labs
Contextual interpretation around biomarker and senior-health panels.
Per-report or co-branded panel.
Hospitals & memory clinics
A standardized dementia-risk workup and longitudinal follow-up layer.
Enterprise pilot and workflow integration.
Specialist clinics
Accessible, per-patient decision support without a heavy platform rollout.
Pay-per-use clinical workflow.
Pharma & CROs
Pre-screening and stratification before costly confirmatory testing.
Screening pilot or program agreement.
06 / ROADMAP
Validate before scale.
The project brief sets a staged path from a demo report and advisory group to lab co-build, hospital validation, broader clinical deployment, and trial intelligence.
01CURRENT
Research + pilot readiness
Demo report, clinical advisory group, partner discovery, test cases.
02NEXT
Lab co-build
Launch a NeuroRisk workflow with an initial diagnostic or clinic network.
03VALIDATE
Hospital study
Run an ethics-reviewed pilot with a memory clinic or tertiary-care partner.
04EXPAND
Clinical distribution
Scale across labs, specialist practices, and enterprise workflows.
05EXTEND
Trial intelligence
Develop pre-screening partnerships with pharma and CRO programs.
PROJECT-REPORTED CURRENT FOCUS
- Five-agent prototype workflow
- Explainability and confidence outputs in the demo
- Research manuscript in process
- Validation and commercialization partnerships sought
07 / TEAM
A cross-functional team for clinical infrastructure.
The project brief brings together neuroscience, AI, deep-tech engineering, hardware, research, and deployment.
Kirtika Goyal
Builder · research & key accounts
Dr. Sharika
Neuroscience medical officer
Harsh Gupta
Deep-tech engineer · AI research
Prajjwal Singh
Hardware engineer
Dr. Daniel
Neuroscience researcher
Ishaan Gupta
Forward-deployed agentic engineer
08 / QUESTIONS
What a first conversation should clarify.
Does PROBRAIN diagnose Alzheimer's?
No. The current product is presented as a research-stage clinical decision-support concept. It is designed to prepare an explainable assessment for clinician review, not to make an autonomous diagnosis.
What data can the system work with?
The product architecture is designed around blood biomarkers, cognition, imaging summaries, clinical history and comorbidities, caregiver or patient-reported change, and longitudinal context.
Who is the initial partner?
The near-term wedge is diagnostic labs and clinical networks, followed by hospitals, memory clinics, specialist practices, and research or trial programs.
What happens in a demo?
The team walks through the signal-fusion workflow, an illustrative clinician report, explainability and confidence markers, and a proposed pilot path for your organisation.
09 / CONTACT
Bring us a workflow.
We'll show where PROBRAIN fits.
For diagnostic labs, hospital teams, memory clinics, research partners, pharma, CROs, and early institutional supporters.